Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc demonstrates a strong positive outlook due to the successful topline results from pivotal Phase 3 trials of its lead asset, phentolamine, in treating presbyopia and keratorefractive surgery patients, indicating a significant gain in visual acuity. The planned submission of a supplemental New Drug Application (sNDA) in the second half of 2025 for presbyopia reinforces the trajectory of potential market entry and revenue generation. The strategic collaboration with Viatris for the commercialization of phentolamine further supports the company’s financial stability and growth prospects in addressing a broad range of retinal and refractive disorders.

Bears say

Opus Genetics faces significant risks that contribute to a negative outlook, primarily due to the uncertainty surrounding the commercial viability of its product candidates, which may not achieve projected peak revenue estimates influenced by market size and penetration rates. Additionally, the company's financial stability may be jeopardized if it fails to secure sufficient capital resources to sustain its operations, impacting ongoing product development and commercialization efforts. Lastly, potential competitive pressures and safety concerns raised by similar products from other companies may hinder Opus Genetics' ability to effectively penetrate the market.

Opus Genetics (IRD) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.